For every CEO, here's key reasons why to engage with PharmaKonsult
Why Joseph McCoy
- 30+ years commercial leadership
- Commercialization plans completed for three start-up companies
- Multiple #1 launches
- Neuroscience expertise
- Rare disease expertise
- Ten-time Pinnacle Club leader
- Former Pfizer, Lundbeck, SK Life Science, Xeris
- Former U.S. Navy Officer
Commercial Advisory
Where biotechnology leadership engages PharmaKonsult
Senior commercial advisory for emerging biotechnology companies preparing for U.S. commercialization, first launch, organizational build-out and board-level commercial decisions.
Practice Areas
Four areas of commercial leadership
PharmaKonsult partners with biotechnology CEOs and boards across the commercial decisions that define company value—from culture and leadership through launch, rare disease, and therapeutic specialization.
Strategic Drug Development & Commercialization Advisory
Strategic advisory across rare disease drug development and commercialization—helping leadership make the decisions that increase regulatory success, adoption, partnerships, and long-term value.
A commercial lens across the development continuum—indication priority, evidence, centers and investigators, partnering, and commercialization sequencing.
Learn More
Commercial Leadership, Culture & Organizational Performance
High-performing commercial organizations are built through exceptional leadership, disciplined execution, and a culture of trust and accountability.
We help biotechnology companies recruit and develop leaders, optimize commercial organizations, and build cultures that sustain long-term performance.
Learn More
Neurology Rare Disease Commercialization
Neuroscience rare disease launches face dispersed patients, long diagnostic journeys, and concentrated Centers of Excellence.
Specialized commercial guidance for assets where diagnosis, access, and stakeholder dynamics are uniquely complex.
Learn More
Endocrinology Rare Disease Commercialization
Endocrinology rare disease markets demand precise stakeholder mapping, access planning, and specialty commercial execution.
Strategy and launch approaches built for these therapeutic realities—and for the patients and physicians who depend on them.
Learn More
